The evolving role of prostate brachytherapy

Cancer Control

Volumn 8, Issue 2, 2001, Pages 163-170

  Beyer, David C ^a  

^a Arizona Oncology Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PATIENT RIGHT; PATIENT SELECTION; PROGNOSIS; PROSTATE CANCER; SCORING SYSTEM;

EID: 0035053274     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800207     Document Type: Article

References (41)

1. Global cancer statistics
2. Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990
3. The national cancer data base report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S.
4. Behavioral patterns of prostate adenocarcinoma following an 125I implant and pelvic node dissection
5. Interstitial radiation therapy for carcinoma of the prostate
6. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography
7. Brachytherapy and organ preservation in the management of carcinoma of the prostate
8. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance: Endocurie/hypertherm
9. Comparative analysis of prostate brachytherapy pre-planning
10. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States
11. A dose-response study for 1-125 prostate implants
12. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy: The clinical research committee of the American Brachytherapy Society
13. Consensus statement: Guidelines for PSA following radiation therapy
14. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma
15. Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
16. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
17. Palladium-103 brachytherapy for prostate carcinoma
18. Permanent prostate brachytherapy: The Arizona experience
19. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate
20. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance
21. 103 Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma
22. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice
23. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
24. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
25. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy
26. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
27. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
28. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy
29. Extent of extracapsular extension in localized prostate cancer
30. Simultaneous radio therapy for prostate cancer: 125 I prostate implant followed by external-beam radiation
31. Transperineal ultrasound guided I125/Pd103 brachytherapy for early stage prostate cancer: Update on clinical experience at seven years
32. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
33. Improved survival in patients with locally advanced prostate cancer treated with radio-therapy and goserelin
34. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate
35. Temporal resolution of urinary morbidity following prostate brachytherapy
36. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
37. Complications and late toxicity following permanent prostate brachytherapy
38. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection
39. Clinical course of rectal bleeding following I-125 prostate brachytherapy
40. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer
41. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer